产品
编 号：F761678
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 943453-46-1
产品详情
生物活性：
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM.
体内研究：
Figitumumab (CP-751871) (31-125 μg/mouse; i.p.; once) induces the down-regulation of tumor associated IGF-1R in mice.Figitumumab (62.5-500 μg/mouse; i.p.; once) inhibits the growth of s.c. xenografts derived from colon (Colo-205), breast (MCF7), and lung (H460) cancer cell lines in mice.Animal Model:Female athymic mice (CD-1 nu/nu) bearing NIH3T3/IGF-1R tumors
Dosage:31 to 125 μg per mouse
Administration:Intraperitoneal injection, once
Result:Resulted in a serum Cmax between 12 and 24 hours. At 24 hours, there was a dose-dependent reduction of IGF-1R protein in tumors, with 50% reduction observed at a serum concentration of 15 μg/mL. Resulted in a down-regulation of IGF-1R from the tumor. The half-life in an athymic mouse was determined to be 4 to 6 days by longer-term studies.
Animal Model:Female athymic mice (CD-1 nu/nu), human Colo-205 tumor xenograft model
Dosage:62.5 μg or 250 μg per mouse
Administration:Intraperitoneal injection, once
Result:Inhibited the tumor growth.
体外研究：
Figitumumab (CP-751871) (152 pM-10 μM; 3 days) inhibits cancer cell proliferation.Figitumumab (1 μg/mL; 1 min or 24 h) induces the down-regulation of IGF-1R.Figitumumab inhibits IGF1-induced autophosphorylation of IGF1R with an IC50 of 0.42 nM, and indirectly inhibits AKT activation.Figitumumab recognizes the IGF-1R/IR heterodimer complex.
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM.
体内研究：
Figitumumab (CP-751871) (31-125 μg/mouse; i.p.; once) induces the down-regulation of tumor associated IGF-1R in mice.Figitumumab (62.5-500 μg/mouse; i.p.; once) inhibits the growth of s.c. xenografts derived from colon (Colo-205), breast (MCF7), and lung (H460) cancer cell lines in mice.Animal Model:Female athymic mice (CD-1 nu/nu) bearing NIH3T3/IGF-1R tumors
Dosage:31 to 125 μg per mouse
Administration:Intraperitoneal injection, once
Result:Resulted in a serum Cmax between 12 and 24 hours. At 24 hours, there was a dose-dependent reduction of IGF-1R protein in tumors, with 50% reduction observed at a serum concentration of 15 μg/mL. Resulted in a down-regulation of IGF-1R from the tumor. The half-life in an athymic mouse was determined to be 4 to 6 days by longer-term studies.
Animal Model:Female athymic mice (CD-1 nu/nu), human Colo-205 tumor xenograft model
Dosage:62.5 μg or 250 μg per mouse
Administration:Intraperitoneal injection, once
Result:Inhibited the tumor growth.
体外研究：
Figitumumab (CP-751871) (152 pM-10 μM; 3 days) inhibits cancer cell proliferation.Figitumumab (1 μg/mL; 1 min or 24 h) induces the down-regulation of IGF-1R.Figitumumab inhibits IGF1-induced autophosphorylation of IGF1R with an IC50 of 0.42 nM, and indirectly inhibits AKT activation.Figitumumab recognizes the IGF-1R/IR heterodimer complex.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备